Syringe injections inherently accompany burst inoculation of a defined volume to cover a sustained period of effect. Considering the combinative need for both release patterns, a user-specified switch between burst and sustained release is required, depending on each therapeutic strategy. Ovarian hyperstimulation syndrome (OHSS) is a representative risk of syringe injections used to stimulate ovulation. Follicle-stimulating hormone (FSH) is injected repeatedly for sustained effects, followed by a last shot of human chorionic gonadotropin (hCG) for burst effects, which accompanies OHSS risks. Hence, a shape memory microneedle (SMN) is developed by enabling recovery from X to O shape by mild heating, switching from sustained to burst release under a single transdermal insertion. The X shape provides sufficient loading spaces for double hormone layers in gelatin gel from outer FSH to inner hCG onto the SMN. After the 3-day sustained release of FSH by controlling gelatin degradation in the X shape, the recovery to the O shape pushes out hCG for a 24-hour burst release with sufficient gelatin breakage in a clinic-mimetic rabbit model. Despite overdose loading with a single shot, the SMN preserves the injection level of ovulation by suppressing OHSS risks, indicating the SMN's potential to address syringe injection issues.